35889-75-9

Upstream product

• 7664-93-9 sulfuric acid 
• 39031-30-6 5,11-bis-(toluene-4-sulfonyl)-5H,11H-dibenzo[b,f][1,5]diazocine-6,12-dione 
• 3808-20-6 4-methyl-N-[2-(4-oxo-4H-benzo[d][1,3]oxazin-2-yl)phenyl]benzenesulfonamide 
• 552-16-9 ortho-nitrobenzoic acid 
• 53705-10-5 ethyl 2-[2-(p-toluenesulfonylamino)benzoylamino]benzoate 
• 228581-79-1 ethyl 2-(2-aminobenzoylamino)-benzoate 
• 326901-33-1 ethyl 2-(2-nitrobenzoylamino)-benzoate 
• 150256-42-1 2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)benzoic acid 
• 610-14-0 2-nitrobenzyl chloride 

Relevant academic research and scientific papers

X-ray diffraction analysis and luminescence spectral study of crystal solvates of N-(N′-tosylanthranoyl)anthranilic acid with acetic acid and dimethylformamide

Two crystal modifications of N-(N′-tosylanthranoyl)anthranilic acid were studied by X-ray diffraction analysis and luminescence spectroscopy. One crystal modification is a crystal solvate with acetic acid and is characterized by green fluorescence. Another modification is a crystal solvate with DMF and exhibits blue fluorescence. The modifications differ in the melting point.

ANTIVIRAL COMPOUNDS

The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections.

Synthesis, biological evaluation, and structure-activity relationships of 2-[2-(benzoylamino)benzoylamino]benzoic acid analogues as inhibitors of adenovirus replication

2-[2-Benzoylamino)benzoylamino]benzoic acid (1) was previously identified as a potent and nontoxic antiadenoviral compound (Antimicrob. Agents Chemother. 2010, 54, 3871). Here, the potency of 1 was improved over three generations of compounds. We found that the ortho, ortho substituent pattern and the presence of the carboxylic acid of 1 are favorable for this class of compounds and that the direction of the amide bonds (as in 1) is obligatory. Some variability in the N-terminal moiety was tolerated, but benzamides appear to be preferred. The substituents on the middle and C-terminal rings were varied, resulting in two potent inhibitors, 35g and 35j, with EC50 = 0.6 μM and low cell toxicity.

NEW ANTIVIRAL COMPOUNDS

The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections.